Trial Profile

A Phase II Open-Label Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of ATL1103 300mg in Adult Patients with Acromegaly.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Apr 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atesidorsen (Primary)
Indications Acromegaly
Focus Adverse reactions; Pharmacokinetics
Sponsors Antisense Therapeutics

Most Recent Events

04 Apr 2017 Status changed from recruiting to completed.
11 Mar 2016 According to Antisense media release, full dosing is expected to be completed in June 2016.
09 Sep 2015 According to Antisense Therapeutics, dosing of patients will be completed by end of this year.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com